Literature DB >> 9068665

Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy.

O Ishikawa1, H Ohigashi, Y Sasaki, T Kabuto, H Furukawa, S Nakamori, S Imaoka, T Iwanaga, T Kasugai.   

Abstract

BACKGROUND: Until recently long-term survival has not been expected when at least one positive node was detected at any site in pancreatic head cancer treated by conventional pancreatectomy. However, even when nodal involvement is seen, there has been an increasing number of long-term survivors after extended pancreatectomy in which a wide range of lymphatic and connective tissues were cleared. Thus the purpose of the present study was to establish a practical rational grouping of positive lymph nodes in pancreatic head cancer treated by extended pancreatectomy.
METHODS: In 81 patients who tolerated extended pancreatectomy for cancer of the pancreatic head, a mean of 56 +/- 23 (range, 28 to 89) lymph nodes in each patient were examined under a microscope to determine the presence or absence of cancer. They were classified anatomically into 14 lymph node groups, and the incidence, distribution, and number of positive nodes were examined. A simplified grouping was made on the basis of the histologic findings and was checked against long-term survival rates.
RESULTS: Nodal involvement was detected in 59 (73%) of 81 patients, and positive nodes were more commonly observed in the posterior pancreaticoduodenal (PPD), superior mesenteric (SM), and anterior pancreaticoduodenal (APD) groups than in the 11 other groups (p < 0.05). The PPD, APD, and SM groups offered the sole sites of nodal involvement with incidence levels of 23%, 17%, and 6%, respectively, whereas none of the 11 other groups did. Thus patients were classified into four groups: (a), negative in all 14 lymph node groups (n = 22); (b), positive but limited to the PPD/APD groups (n = 14); (c), also positive in the SM group, but negative in the 11 other groups (n = 13); and (d), also positive in at least one of the 11 other groups (n = 32). This classification was associated well with the 5-year survival rate: 59% in group (a), 53% in group (b), 15% in group (c), and 0% in group (d) [p < 0.05; group (b) versus group (c)]. Also this grouping associated well with the total number of positive nodes (p < 0.05). The 5-year survival rate in patients with one to three positive nodes was 47% and was more than 6% in patients with four to seven positive nodes (p < 0.05).
CONCLUSIONS: In the clinicopathologic staging of the lymphatic spread from carcinoma of the pancreatic head, the PPD and APD groups were considered the first stations of lymphatic metastasis, whereas the 12 other groups-including the SM group-were categorized as second or more distant stations.

Entities:  

Mesh:

Year:  1997        PMID: 9068665     DOI: 10.1016/s0039-6060(97)90352-4

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

Review 1.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  Can intestinal innervation be preserved in pancreatoduodenectomy for cancer? Results of an anatomical study.

Authors:  M Nano; H Dal Corso; M Ferronato; M Solej; J P Hornung
Journal:  Surg Radiol Anat       Date:  2003-02-25       Impact factor: 1.246

Review 3.  The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence.

Authors:  Michael B Farnell; Gerard V Aranha; Yuji Nimura; Fabrizio Michelassi
Journal:  J Gastrointest Surg       Date:  2007-12-18       Impact factor: 3.452

4.  Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry.

Authors:  M Carpelan-Holmström; S Nordling; E Pukkala; R Sankila; J Lüttges; G Klöppel; C Haglund
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery.

Authors:  Prejesh Philips; Erik Dunki-Jacobs; Steven C Agle; Charles Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2014-08-15       Impact factor: 3.647

6.  The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment.

Authors:  N Volkan Adsay; Olca Basturk; Deniz Altinel; Fayyaz Khanani; Ipek Coban; Donald W Weaver; David A Kooby; Juan M Sarmiento; Charles Staley
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

7.  Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence.

Authors:  Wenjie Sun; Cheng N Leong; Zhen Zhang; Jiade J Lu
Journal:  Radiat Oncol       Date:  2010-04-15       Impact factor: 3.481

8.  Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?

Authors:  Ioannis T Konstantinidis; Vikram Deshpande; Hui Zheng; Jennifer A Wargo; Carlos Fernandez-del Castillo; Sarah P Thayer; Vasiliki Androutsopoulos; Gregory Y Lauwers; Andrew L Warshaw; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

9.  Extended lymphadenectomy in patients with pancreatic cancer is debatable.

Authors:  Gregory Sergeant; Emmanuel Melloul; Mickael Lesurtel; Michelle L Deoliveira; Pierre-Alain Clavien
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

10.  Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer.

Authors:  Michael G House; Mithat Gönen; William R Jarnagin; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Murray F Brennan; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2007-09-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.